Psychiatric Drug Facts via breggin.com :

“Most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems… Withdrawal from psychiatric drugs should be done carefully under experienced clinical supervision.” Dr. Peter Breggin
Showing posts with label PTSD. Show all posts
Showing posts with label PTSD. Show all posts

Feb 2, 2013

Psychiatric Drugs are Killing American Soldiers


 US Marine, Afghanistan

Marine patroling a poppy field in Afghanistan. Photograph: Patrick Baz/AFP/Getty Images

via The Guardian:
Datablog badge new 620
Friday 1 February 2013 12.00 EST






Simon Rogers
US military suicides in charts: 
how they overtook combat deaths
US military suicides are increasing as deaths in action are going down. 
Find out what we know about the trend• Download the data
More data journalism and data visualisations from the Guardian


US military suicides have never been so high since data was recorded:up to 349 for 2012.
It exceeded the Pentagon's own internal projection of 325. US government began closely tracking suicides in 2001 through the Department of Defense Suicide Event Report (DoDSER). It exceeds the 311 Americans who died in war zones last year. read the rest here
By the way...

Why in the hell are American soldiers guarding poppy fields?  Intentionally or not, it facilitates  "greater heroin availability, rising purity, and lower prices." 



Beginning of original post from 8-23-2011:



Antidepressants, neuroleptics and other psychiatric drugs can kill the person who takes them, or compel the person to commit acts of violent aggression including homicide.  Why are these events, and the psychiatric drugs which contribute to and/or cause them, not being reported more accurately in the news in the United States?  Does the income derived from direct-to-consumer advertising of drugs serve another purpose?  Is the mainstream news media not reporting the news due to a Conflict of Interest? Is deriving so much revenue from the pharmaceutical industry preventing journalists from accurately reporting stories which are unfavorable or critical of a source of income for their corporate employers?  The United States and New Zealand are the only countries in the world where it is legal to market prescription drugs direct to consumers through print, electronic, radio and television advertisements.  
Who does all of this benefit most?
VIA: Scoop - Independent News



Are US Soldiers Suicides Caused by Prescription Drugs?

by Martha Rosenberg,


Chicago 


"The suicide rate among US troops is astonishing.

"In 2009 there were 160 active duty suicides, 239 suicides within the total Army including the Reserves, 146 active duty deaths from drug overdoses and high risk behavior and 1,713 suicide attempts, says the Army's suicide report, released in July.

"Not only are more troops dying from their own hand than combat says the Army report, titled Health Promotion, Risk Reduction, Suicide Prevention, 36 percent of the suicides were troops who were never deployed.

"Also astonishing is the psychoactive drug rate among active duty-aged troops, 18 to 34, which is up 85 percent since 2003 according to the military health plan, Tricare. Since 2001, 73,103 prescriptions for Zoloft have been dispensed, 38,199 for Prozac, 17,830 for Paxil and 12,047 for Cymbalta says Tricare 2009 data, which includes family prescriptions. All of the drugs carry a suicide warning label.

"In addition to the leap in SSRI antidepressants, prescriptions for the anticonvulsants Topamax and Neurontin rose 56 percent in the same group since 2005 says Navy Times, drugs which the FDA warned last year double suicidal thinking in patients.... "


"Over 4,000 published reports of violent and bizarre behavior of people affected by antidepressants on the web archive ssristories.com reveal the same out of character violence and self harm in civilians, currently seen in the military.

"Twenty people set themselves on fire. Ten bit their victims (including a biter who was sleepwalking and a woman, on Prozac, who bit her 87-year-old mother into critical condition.) Three men in the 70s and 80s attack their wives with hammers. Many stab their victims obsessively -- one even stabs furniture after killing his wife -- and 14 parents drown their children, a crime seldom heard of before the 2001 Andrea Yates case. Yates drowned her five children on the antidepressant Effexor which manufacturer Wyeth (now Pfizer) "issued no public warning" about says the Associated Press.

"Then there's the North Carolina pilot on Zoloft who sings, "I'm going down for the last time," into the cockpit voice recorder before he crashes his plane in June. And the Mayor of Coppell, Texas, Jayne Peters who kills herself and her daughter in July over the grief of losing her husband. Police find antidepressants at the home.

"Such murder-suicides committed by women used to be rare says Betty Henderson the web site's moderator and researcher. "Before the SSRI antidepressants, women committed five percent of the murder-suicides and now they account for almost 15 percent of this type of violence," she said in an interview.

"Antidepressants are also causing women to become neo sexual predators says Henderson. "There have been more than a dozen recent cases of women school teachers molesting their young students under the influence or withdrawal of antidepressants. Who heard of this type of sexual aberration before the antidepressant craze?"

"In fact, the high percentage of civilian suicides on psychoactive drugs is probably the clearest indication that military life is not the only cause of the shocking troop suicides: In September alone, there were 18 civilian suicides, 11 murders, 2 murder suicides and other violence linked to people who were using or had used antidepressants, according to published reports.

"Also in the thirty day period, a 60-year-old grandmother in Seattle killed three family members and herself; a disc jockey in Bristol, UK set himself on fire; and a man in Exeter, UK man was determined to have stabbed himself in the heart. All were on antidepress-ants. Finally, in the month of September, legal proceedings began against two mothers and a father charged with killing their own children. read here.


Via: 9News in Australia:


Suicide brings a decade of war home


12:30 AEST Tue Aug 23 2011


A soldier kills himself and his wife. Another war veteran hangs himself in despair. Yet a third puts a gun to his head and pulls the trigger outside a gas station in a confrontation with Texas lawmen.
Suicides by veterans like these once would have left people reeling in this military community. But troops and their families here these days call it the "new normal" for a US Army that's spent a decade at war.
Melissa Dixon sees the stress in the tattoos she draws on soldiers back from combat.
"Some of them have issues with their wives or their loved ones, where they're fighting, or one will have a friend commit suicide," she said.
There's no place like Fort Hood in the Army. A post that sent soldiers from two divisions to Iraq three times since the invasion, it's logged more suicides since 2003 than any other — 107.
Soldiers at big posts like Fort Hood that have played key roles in deployments are at the greatest risk of killing themselves.
The post here in Killeen, northwest of Texas' state capital, Austin, set an Army record last year with 22 suicides.


Elsewhere, Fort Bragg, North Carolina, home of the 82nd Airborne Division, has lost 77 soldiers to suicide since 2003.
At Fort Campbell, Kentucky, home to the 101st Airborne Division, 75 soldiers have died by their own hand over the last eight years.
But the problem is widespread. Last year, a record 300 soldiers in the active-duty, Reserve and National Guard killed themselves.
The numbers appear to be down slightly in 2011, but 32 active-duty staff killed themselves in July, the highest since the Army began tracking the phenomenon in January 2009.  read the rest here.
SSRI Stories Note: The Physicians Desk Reference states that antidepressants can cause a craving for alcohol and can cause alcohol abuse.   Also, the liver cannot metabolize the antidepressant and the alcohol simultaneously, thus leading to higher levels of both alcohol and the antidepressant in the human body.

via guestofaguest.com from 2007


We came across something very disturbing in today's Metro.  In an article titled"A Soldier's Suicide: Did He Have to Die?" we read about the story of soldier Jason Scheuerman.  Jason took his own life in Iraq after numerous displays of suicidal characteristics and behaviors.  What was more horrifying was this statistic, imbedded halfway down in the article:
"At least 152 U.S. troops have taken their own lives in Iraq and Afghanistan since the two wars started, contributing to the Army's highest suicide rate in 26 years of keeping track."
This is so, so sad.  Not only are we loosing thousands of troops to the enemy (whoever that may be at the time), we are loosing hundreds of sons and daughters to despair.  And it doesn't end when they return home.  America is suffering an epidemic of suicides among traumatized army veterans.
"More American military veterans have been committing suicide than US soldiers have been dying in Iraq. At least 6,256 US veterans took their lives in 2005, at an average of 17 a day." [TimesOnline]
 As a nation, we need to step things up.  Jason is an example of several military leaders failing to take action.  On a mental health questionnaire he had admitted thoughts about killing himself, also that he was uptight, anxious, depressed, and had feelings of hopelessness and despair.  He had also made calls home saying goodbye, and spoke several times about wanting to kill himself.  His leaders many of the times played these claims of his off as exaggerated jokes by the soldier, and even gave him back his gun after serving him with 14 days of extra duty as punishment (minutes later they found him dead in his room).  Imagine the angst of his parents, who were soldiers themselves, and feel this should have been prevented.  His dad Chris:
"We will not see a statistical decrease in Army suicides until the Army gets serious about holding people accountable when they do not do what they are trained to do."
It IS time for our leaders both in the military and back home to step up and start aiding in the mental health of our troops and our veterans. Read it here.
Check out the website SSRI Stories link to stories specific to members of the military and veterans

Dec 6, 2012

Suicide triggers lawsuit against Veterans Administration

via Air Force Times:
Sister’s suicide triggers lawsuit against VA

By Patricia Kime - Staff writer
Posted : Thursday Dec 6, 2012 18:38:38 EST
a few excerpts:
On Veterans Day 2010, former Navy corpsman Kelli Marie Grese, 37, swallowed an unknown quantity of the antipsychotic Seroquel — her fourth suicide attempt in eight months using the same drug.
That time, she succeeded. She never regained consciousness.
Her death is the subject of a $5 million lawsuit filed against the Veterans Affairs Department in the U.S. District Court in Newport News, Va., alleging VA physicians failed to monitor her medications and prescribed them excessively.
Her twin sister, Darla Grese, also a former Navy corpsman, filed the suit, saying physicians at Hampton VA Medical Center, Va., ignored her pleas to quit doling out prescriptions to her sister, a known addict deemed at “moderate risk for suicide.”
“I’m hoping better attention will be placed on how many pills are being written and quantities,” said Darla Grese.
Darla Grese said she filed the lawsuit because she would like to see VA doctors communicate better and pay closer attention to their own patients’ records.

“I don’t understand how a physician can write a prescription for 450 pills and two months later write another prescription for 450,” she said. “Something’s broken. The system is broken.”

Dec 5, 2012

A Seeding Trial: Side Effects of Newer Antipsychotics in Older Adults updated

Trust me I'm a Ducktor
Updated on 12-5-2012
This is a comment that I left on the Mad in America website:
Being unethical doesn’t mean it does not happen. It does. In my opinion, off label prescriptions of psychotropic drugs, particularly prescriptions which are not based on clinical trial evidence, or even minimally supported by data about the drugs’ safety and effectiveness, (which is more common than not, in psychiatry) is Human Experimentation. Calling it “Off Label” instead of calling it what it is, is deceptive; and I believe it is done to deceive. This off label prescribing is theoretically supposed to be based on actual evidence of safety and efficacy, even if it is not from drug trials; the drugs have been in use for a very long time and STILL there is not the evidence available that what is being done in Standard Clinical practice is supported by EVIDENCE. So how the hell did this become a STANDARD PRACTICE? By a using a quasi-democratic process of collaboration and consensus of a few followed by the vote of a few more.  A group of people in effect have determined that voting on their own educated opinions and reaching a consensus is how to develop an "Evidence Base" for psychopharmacology.  Consensus is evidence of agreetment, it is not a substitute for the empirical data required to ethically justify implementing any medical care standard.  It is a dishonest and not at all ethical to use a collection of subjective opinions and observations AS IF they become scientific evidence by virtue of the number or "importance" of the individuals offering them.  Subjective observation is used to SUPPORT objective information NOT replace it... What are the Standards of Care in psychiatry, ie. practice parameters, treatment algorithms, etc. if they are not science-based ethical medical standards?  What the Standards of Care in psychiatry are is an affirmative defense for allegations of medical malpractice. In effect, and in fact, Human Experimentation without the knowledge or the consent of the human participants is standard practice it's "psycho" pharmacology!  

beginning of original blog post
Recently the disappointing outcome of a study using 4 neuroleptic drugs, called "atypical antipsychotics," was reported by UC San Diego and published in the online Journal of Clinical Psychiatry.  When I first read about this study at 1 Boring Old Man's blog, something seemed seriously wrong; but I couldn't put my finger on it right away. After doing a little digging, I realized what was bothering me. It appears the study was a seeding trial, conducted in an (unsucessful) attempt to "legitimize" gain FDA approval for what is being done in standard practice, the off-label prescription use of the drugs known to be ineffective for treating PTSD, Alzheimer's Disease, and Dementia.  All four drugs have an FDA Block Box Warning for increased mortality when used to treat dementia; i.e. dementia is not an FDA approved indication for the drugs used in this trial. Another condition mentioned by the UC San Diego press release is PTSD; PTSD is not an FDA approved indication for the drugs either. In fact, PTSD is not even mentioned among the three conditions listed for intervention with this drug study at ClinicalTrials.gov.

via UC San Diego Health System:

Four Common Antipsychotic Drugs Found to Lack Safety and Effectiveness in Older Adults

some excerpts:
"In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications – schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs." (emhasis mine) 

The study looked at four atypical antipsychotics (AAPs) – aripiprazole (Abilify), olanzapine (Zyprexa), quetiapine (Seroquel), and risperidone (Risperdal) – in 332 patients over the age of 40 diagnosed with psychosis associated with schizophrenia, mood disorders, PTSD, or dementia. (emphasis mine) 
“Our study suggests that off-label use of these drugs in older people should be short-term, and undertaken with caution,” said Dilip V. Jeste, MD, Estelle and Edgar Levi Chair in Aging, Distinguished Professor of Psychiatry and Neurosciences, and director of the Stein Institute for Research on Aging at UC San Diego.
"Results of the five-year study led by Jeste, who is also current president of the American Psychiatric Association (which was not involved in this research), showed that within one year of treatment, one-third of the patients enrolled in the study developed metabolic syndrome (medical disorders that can increase the risk of cardiovascular disease or diabetes). Within two years, nearly a quarter of the patients developed serious adverse effects and just over half developed non-serious adverse effects." here

The FDA approved indications for the 4 drugs used in this study are here

All of the drugs used in this drug trial have black box warnings from the FDA for causing increased mortality for elderly with dementia. The UC San Diego article states, some of the drugs, "carry FDA warnings."  The actual number of participants enrolled in the trial was 406, according to the ClinicalTrials.gov website; why would the the UC San Diego announcement state there were only 332?  PTSD and mood disorders are not listed with the conditions participants were to be treated for on the Clinical Trials website; schizophrenia, Alzheimer's Disease, and dementia are the conditions listed. The only one that is an FDA approved condition is schizophrenia.  The end points were safety and efficacy, which is standard for an "investigational" drug trial, Clinical Trials.gov states this was an investigational Phase 1 trial for the first few years of the trial.  

On October 18, 2012 "Active Control" was deleted from the list of  design characteristics for this study. The responsible party, Dilip V. Jeste, and UCSD was changed to "sponsor" on the same  date.  On April 11, 2009 the Seroquel arm was discontinued, and the answer for the  "accepts healthy volunteers" question was changed from "NO" to "Yes."  A Data Monitoring Committee was also added at the same time.  On February 29, 2008 the classification for this trial was changed from a Phase 1 drug trial to a Phase 4 drug trial; The lead sponsor was changed from being listed as the NIMH to being listed as UCSD; and Dilip V. Jeste, at UCSD, was listed as now being the responsible party, usually the responsible party the lead investigator, would also be the lead author, but in this case Dilip V. Jeste, the President of the American Psychiatric Association, is said to be the lead investigator but is not the lead author.  This study started with The Veterans Medical Research Foundation as the lead sponsor, then the lead sponsor was the NIMH, and upon the study's conclusion, the VMRF is once again listed as the lead sponsor and the NIMH is listed as a collaborator. 

"The bottom line is no solid evidence-based treatment exists for psychosis or agitation in dementia. Atypical antipsychotics carry a black-box warning for increased risk of death and cerebrovascular events in dementia, although typical antipsychotics appear no safer." Thomas W. Meeks, M.D. and Dilip V. Jeste, M.D. in Beyond the Black Box: What is The Role for Antipsychotics in Dementia? 2008

via Physicians Postgraduate Press:
Use of Clinical Markers to Identify Metabolic Syndrome in Antipsychotic-Treated Patients
J Clin Psychiatry 2010;71(10):1273–1278
10.4088/JCP.09m05414yel
Copyright 2010 Physicians Postgraduate Press, Inc.
Objective: Metabolic syndrome (MetS) is prevalent among antipsychotic-treated patients; however, in psychiatric clinics, scarce resources often limit the feasibility of monitoring all 5 criteria that are necessary for diagnosing MetS. As one goal of the MetS definition is to facilitate the clinical identification of insulin-resistant individuals, other biomarkers of insulin resistance have been explored. However, there are relatively few data from antipsychotic-treated patients, especially on the association between these markers and the clinical MetS diagnosis.

Method: We analyzed data from 196 psychiatric patients over age 40 years enrolled in an ongoing study of antipsychotic-related metabolic effects that began in August 2005. here

Black Box Warning from The U.S. Department of Health and Human Services FDA

Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances

4/11/2005

The Food and Drug Administration has determined that the treatment of behavioral disorders in elderly patients with dementia with atypical (second generation) antipsychotic medications is associated with increased mortality. Of a total of seventeen placebo controlled trials performed with olanzapine (Zyprexa), aripiprazole (Abilify), risperidone (Risperdal), or quetiapine (Seroquel) in elderly demented patients with behavioral disorders, fifteen showed numerical increases in mortality in the drug-treated group compared to the placebo-treated patients. These studies enrolled a total of 5106 patients, and several analyses have demonstrated an approximately 1.6-1.7 fold increase in mortality in these studies. Examination of the specific causes of these deaths revealed that most were either due to heart related events (e.g., heart failure, sudden death) or infections (mostly pneumonia). read the rest here
 via Physician's Post Graduate Press:

Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40: A Trial Using Equipoise-Stratified Randomization
J Clin Psychiatry
10.4088/JCP.12m08001
Copyright 2012 Physicians Postgraduate Press, Inc.

Objective: To compare longer-term safety and effectiveness of the 4 most commonly used atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) in 332 patients, aged > 40 years, having psychosis associated with schizophrenia, mood disorders, posttraumatic stress disorder, or dementia, diagnosed using DSM-IV-TR criteria.
Method: We used equipoise-stratified randomization (a hybrid of complete randomization and clinician’s choice methods) that allowed patients or their treating psychiatrists to exclude 1 or 2 of the study atypical antipsychotics due to past experience or anticipated risk. Patients were followed for up to 2 years, with assessments at baseline, 6 weeks, 12 weeks, and every 12 weeks thereafter. Medications were administered employing open-label design and flexible dosages, but with blind raters. The study was conducted from October 2005 to October 2010.
Outcome Measures: Primary metabolic markers (body mass index, blood pressure, fasting blood glucose, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), percentage of patients who stay on the randomly assigned atypical antipsychotic for at least 6 months, psychopathology, percentage of patients who develop metabolic syndrome, and percentage of patients who develop serious and nonserious adverse events.
Results: Because of a high incidence of serious adverse events, quetiapine was discontinued midway through the trial. There were significant differences among patients willing to be randomized to different atypical antipsychotics (P < .01), suggesting that treating clinicians tended to exclude olanzapine and prefer aripiprazole as one of the possible choices in patients with metabolic problems. Yet, the atypical antipsychotic groups did not differ in longitudinal changes in metabolic parameters or on most other outcome measures. Overall results suggested a high discontinuation rate (median duration 26 weeks prior to discontinuation), lack of significant improvement in psychopathology, and high cumulative incidence of metabolic syndrome (36.5% in 1 year) and of serious (23.7%) and nonserious (50.8%) adverse events for all atypical antipsychotics in the study.
Conclusions: Employing a study design that closely mimicked clinical practice, we found a lack of effectiveness and a high incidence of side effects with 4 commonly prescribed atypical antipsychotics across diagnostic groups in patients over age 40, with relatively few differences among the drugs. Caution in the use of these drugs is warranted in middle-aged and older patients.    here

via ClinicalTrials.gov:

Side Effects of Newer Antipsychotics in Older Adults

Purpose
This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.

Condition                                                Intervention                                                   Phase
Schizophrenia                                         Drug: Aripiprazole                                         Phase 4
Alzheimer's Disease                                Drug: Olanzapine
Dementia                                                Drug: Risperidone


Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Metabolic Effects of Newer Antipsychotics in Older Patients

Detailed Description:

Atypical antipsychotic medications introduced within the last decade have been used increasingly for the treatment of several types of psychotic disorders and severe behavioral disturbances in older individuals. This trend is primarily due to a decrease in side effects caused by the new medications, as compared to conventional neuroleptic medications. There is a lower risk for developing tardive dyskinesia and extrapyramidal symptoms, both of which are movement abnormalities, with new antipsychotic medications. However, there has been a growing concern that the newer medications can cause a different set of potentially serious adverse side effects. Specifically, they may cause long-term metabolic, cardiovascular, and cerebrovascular effects, which may result in weight gain, diabetes, or stroke. This study will compare four atypical antipsychotic medications in terms of the risk of metabolic, cardiovascular, and cerebrovascular side effects that each presents in middle-aged and elderly individuals.

Participants in this open-label study will be randomly assigned to receive one of three atypical antipsychotic medications: aripiprazole; olanzapine; or risperidone. Although assignment is random, a technique that may reflect the participant's own interests or the researcher's knowledge of relevant participant characteristics will be used to assign the participant to a medication. Dosing will be determined by each participant's psychiatrist. Participants will be followed for up to 5 years to assess the side effects of the study medications, with study visits at baseline, Week 6, and every 3 months thereafter.

Ages Eligible for Study: 40 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes

Criteria
Inclusion Criteria:
DSM-IV diagnosis of a disease or disorder that requires treatment with an atypical antipsychotic medication

Exclusion Criteria:
N/A here





photo credit Just Ducks

Aug 14, 2012

Ducktors Nemeroff and Insel: quacks can't be Kosher...

Ducktors Thomas Insel and Charles Nemeroff 

The investigation is OPEN.
It is a clearly a questionable decision to award a Federal Grant to a psychiatrist whose conduct has been under investigation by both the Office of Inspector General for Health and Human Services and the Department of Justice for quite some time.  It is simply unethical to award Charles Nemeroff a grant prior to the investigation being over.  That is exactly what has happened though. The investigation has been completed; but the DOJ has not announced whether it will be filing criminal charges or lettting Nemeroff off the hook. 

The grant Nemeroff was awarded is to study the neurpsychobiological risk factors for post-traumatic stress disorder. Translation: Chuck is being paid to hunt down the evidence needed to declare  Post-Traumatic Stress Disorder is a neurobiological disease. ($$$ good!)
4 out of 5 psychiatrists recommend Ethic-Eze
IT'S NOT JUST FOR Ad Men any more!



Ed Silverman's article and the comment left by 1Boring Old Man are a must read.  Ed's article and 1 Boring Old Man's comment lay out the disturbing facts about how Insel purposely minimized the egregious nature of Nemeroff's unethical conduct, then helped to secure him a faculty position at another public institution of Higher Learning, the University of Miami. By all appearances, unethical behavior was dismissed or minimized.  It appears that a plan for Nemeroff to avoid the consequences that NIH and Emory had laid out for his unethical conduct was planned and executed by the Director of the National Institutes of Mental Health, Thomas Insel, and the unscrupulous Charles Nemeroff.  One doesn't have to be a Rabbi to know that Nemeroff and Insel's unethical conduct destroys altogether the delusion that ethical integrity is valued by psychiatric researchers or valued by the Director of NIMH.


Ducktors Insel and Nemeroff are not even close to Kosher...

via Pharmalot:

NIH Insists Latest Nemeroff Grant Is Kosher

Jul 16, 2012

Neurotrauma and Psychological Health Project and Cooperative Studies

Violating the Hippocratic Oath and the Oath to preserve and defend the Constitution.


via Stars and Stripes:


Army, VA partner for PTSD drug study

"An Army office at Fort Detrick and a veterans program are teaming up to study drugs that could help treat combat-related post-traumatic stress disorder.


"The U.S. Army Medical Materiel Development Activity's Neurotrauma and Psychological Health Project Management Office has signed an agreement with the Department of Veterans Affairs Cooperative Studies Program that will help guide the studies, which could begin in about a year.


"Clinical studies at locations across the U.S. will take an additional 24 to 36 months to complete, according to Maj. Gary Wynn of USAMMDA, which is based at Fort Detrick.


"We're not just looking to do a study, we're looking to do a program," Wynn said.


"Wynn, a research psychiatrist who also works at Walter Reed National Military Medical Center in Bethesda, is chairing the effort for the Department of Defense.


"The goal is to identify drugs already on the market that may help in treating PTSD and seek U.S. Food and Drug Administration approval for their specific use in treating the disorder, Wynn said. In some cases, health care providers may already be using certain drugs off-label to help, Wynn said, but they are not approved for use.


"Providers have found certain drugs help aspects of (PTSD), but nothing has been studied to the FDA level," Wynn said.


"Only two drugs, paxotene, known as Paxil, and Zoloft, are approved for the treatment of PTSD, Wynn said.


"The disorder's symptoms include flashbacks, loss of sleep and nightmares. Its cause is unknown, according to the National Institutes of Health.


"Studies have shown that 10 to 15 percent of soldiers who deploy in a given year may develop PTSD, Wynn said.


"Researchers are eyeing 10 to 20 drugs that might be helpful for treatment, Wynn said, including Seroquel, an antipsychotic, and Lunesta, which is used to treat insomnia." here

This announcement comes less than three months after the Army Surgeon General and Army Medical Command warned doctors against using psychotropic drugs for PTSD; citing fatal risks and lack of efficacy.

The question is why is the DoD and the Department of Veterans Affairs partnering to study drugs that are known to have fatal risks when it is known the drugs are not effective treatment for PTSD? The answer is given by Major Gary Wynn; a psychiatrist, who reports the purpose of the drug trials will be to, "seek U.S. Food and Drug Administration approval for their specific use in treating" PTSD.  This is not a valid ethical purpose for conducting a drug trial using human subjects. It is what is referred to as a 'seeding trial,' the primary purpose of which is to expand the market for a particular drug; or in this case, multiple drugs.  Why is the US Government planning on conducting and paying for research which is obviously unethical, and plainly nothing more than a part of the pharmaceutical industry's drug marketing strategy?

Why is the DoD and Veterans Affairs not announcing that it is going to make it a priority to fund the type of treatment that has empirical evidence of being effective for treating PTSD?  Apparently, ensuring that the military continues to be a source of revenue long term for the pharmaceutical industry takes precedence over providing effective non-lethal treatment for our troops with Post Traumatic Stress Disorder.


Major Gary Wynn is a psychiatrist and is going to head this project.  Since the drugs are already known to be ineffective, and multiple warnings have been issued cautioning against using them to treat PTSD due to risk of fatality and the drugs inefficacy; it is a violation of the ethical guidelines of the medical profession, to even prescribe them for PTSD. "First, do no harm..." These drug trials are not for the primary benefit of the troops who have PTSD. It is obvious that the preservation and defense of the individual rights; i.e. Constitutional Rights, of the troops who will be used as research fodder in what is clearly Human Experimentation is not even a concern; it's morally reprehensible. 


last month in Navy Times:
DoD cracks down on off-label drug use
"The message from Air Force Lt. Gen. Brooks Bash informed White that U.S. Central Command had decided in March to remove the powerful antipsychotic drug Seroquel from its approved formulary list." here


via Air Force Times: 
Army launches study of PTSD meds
By Patricia Kime - Staff writer
Posted : Tuesday May 8, 2012 16:21:49 EDT

"Military and Veterans Affairs Department physicians often prescribe medication to ease the symptoms of combat-related post-traumatic stress disorder, even though only two antidepressants — Paxil and Zoloft — are approved specifically by the Food and Drug Administration to treat the disorder.

"But little data exists on which “off-label” medications work and which don’t.

"The Army is hoping to change this, launching a major research initiative next year on the effectiveness of commonly prescribed medications for PTSD.

"Speaking at the American Psychiatric Association meeting in Philadelphia on Monday, Army Maj. Gary Wynn of the Walter Reed Army Institute of Research and Col. David Benedik, associate director for the Center for the Study of Traumatic Stress at the Uniformed Services University of the Health Sciences, said the service will start clinical trials next year to evaluate commonly prescribed PTSD medications such as the antidepressant Cymbalta, mirtazapine, prazosin, and atypical antipsychotics like Seroquel." 
here

via NextGov Broken Warriors April 25, 2012:

ARMY WARNS DOCTORS AGAINST USING CERTAIN DRUGS IN PTSD TREATMENT


"The Army Surgeon General's office is backing away from its long-standing endorsement of prescribing troops multiple highly addictive psychotropic drugs for the treatment of post-traumatic stress disorder and early this month warned regional medical commanders against using tranquilizers such as Xanax and Valium to treat PTSD.

An April 10 policy memo that the Army Medical Command released regarding the diagnosis and treatment of PTSD said a class of drugs known as benzodiazepines, which include Xanax and Valium, could intensify rather than reduce combat stress symptoms and lead to addiction.


The memo, signed by Herbert Coley, civilian chief of staff of the Army Medical Command, also cautioned service clinicians against prescribing second-generation antipsychotic drugs, such as Seroquel and Risperidone, to combat PTSD. The drugs originally were developed to treat severe mental conditions such as schizophrenia and bipolar disorder. The memo questioned the efficacy of this drug class in PTSD treatment and cautioned against their use due to potential long-term health effects, which include heart disorders, muscle spasms and weight gain."  read here


via NextGov Broken Warriors August 2011: 
VA SPENT $717 MILLION ON A DRUG DEEMED AS EFFECTIVE AS A PLACEBO
"Over the past decade, the Veterans Affairs Department spent $717 million for an anti-psychotic drug to treat post-traumatic stress disorder that a recent study shows is no more effective than a placebo."

"While the paper on risperidone published earlier this month reported the results of the first large trial measuring the effectiveness of second-generation anti-psychotics in the treatment of PTSD, previous research found little evidence the drugs were effective and VA's own clinical practice guidelines, first published in 2004, when the department spent $66 million on risperidone and $56 million on Seroquel, warned against using the drugs to treat PTSD." here


In 2011 it was announced that Venlafaxine became a "First- Line Treatment" for PTSD even though it is not FDA approved to treat PTSD.

via Clinical Psychiatry News 3-11-11
Venlafaxine Becomes First-Line PTSD Therapy in Latest VA Guidelines


"The new Veterans Affairs/Department of Defense (VA/DoD) evidence-based guidelines strongly recommend that all adults with PTSD be offered pharmacotherapy with a first-line agent. That means either an SSRI, for which the strongest evidence of benefit exists for sertraline, paroxetine, and fluoxetine, or a serotonin norepinephrine reuptake inhibitor (SNRI), among which venlafaxine has the strongest supporting evidence, said Dr. Villarreal, a psychiatrist at the University of New Mexico, Albuquerque, and the New Mexico VA Health Care System." here

American Veterans: They Made It Back Alive To Die Here At Home

US Marine Corp Printable Flag PictureArmy Printable Flag PictureAir Force Printable Flag PictureVietnam Veterans Printable Flag PictureNavy Printable Flag PictureUSMC Free Downloadable Marines Desktop Background






This was first posted on October 25, 2010.  Updated on 7-16-2012  Almost every day I see a veteran who is experiencing PTSD as a result of fighting for Our Country.  We as a Nation owe them our gratitude and support.  I wish I could do more.

It is a National disgrace.  Our walking wounded returning from the fields of battle in Iraq and Afghanistan suffering from PTSD, for which they receive "treatment" that may be "standard practice;" but it is not evidence-based. It is actually deadly for some.

Report to Army Surgeon General on veterans dying in their sleep by Fred Baughbam, Jr. M.D., on resne.com 1.94MB pdf
http://www.rense.com/general90/sleep.htm:


Link to article in Washington Times of a family taking their concern to Capital Hill:
http://www.cplchado.org/articles/WashingtonTimes_11-13-08CplAWhite.pdf


via Navy Times:
DoD cracks down on off-label drug use

By Patricia Kime - Staff writer
Posted : Thursday Jun 14, 2012 10:01:04 EDT
A letter landed in Stan White’s mailbox in Cross Lanes, W.Va., in April.
It began: “On behalf of the men and women of the U.S. Armed Forces … I extend my sincerest and deepest sympathy for the loss of your sons.”
But the note wasn’t simply a condolence. The message from Air Force Lt. Gen. Brooks Bash informed White that U.S. Central Command had decided in March to remove the powerful antipsychotic drug Seroquel from its approved formulary list.
Under the new rules, CENTCOM doctors now must request a waiver if they write a prescription for Seroquel, also known as quetiapine.
The change is a small victory for White, who had already lost one son to combat and has sought restrictions on the drug he believes contributed to the death of a younger son.
Marine Cpl. Andrew White died Feb. 12, 2008, at age 23 from a lethal combination of medications prescribed for post-traumatic stress disorder, mainly clonazepam, quetiapine and paroxetine — the latter two known to sometimes affect the heart’s regular rhythm. read here



They fought for us; it is time the American people fight for them and their families' right to the truth, and our Veteran's rights to the kind compassionate care required to achieve victory here at home over the harms suffered abroad.  Write your state and US Senators and Representatives take a stand for our returning heroes.


A special thanks to Duane Sherry for sharing this resource Patriot Outreach:
http://www.patriotoutreach.org/

LinkWithin

Related Posts Plugin for WordPress, Blogger...

FAIR USE NOTICE: This may contain copyrighted
(C) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.